SEC Filings TLDR

This Amendment No. 12 to Schedule 13D, filed by ValueAct Capital and related entities, updates their ownership and transactions in the common stock of Insight Enterprises, Inc. As of the filing date, the reporting persons collectively own 1,666,739 shares, representing approximately 5.3% of the outstanding common stock...

TransCode Therapeutics, Inc. filed an amendment to its Schedule 13D, originally submitted on October 16, 2025. The amendment includes updates to the Contingent Value Rights (CVR) Agreement, which entitles holders of Common Stock as of October 20, 2025, to receive CVRs. These CVRs grant holders 50% of the Net Proceeds f...

This filing represents Amendment No. 1 to the Schedule 13D previously filed by Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Dr. Brian Liu regarding their holdings in CG Oncology, Inc. The amendment reflects an internal restructuring into a master-feeder struc...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz, Steven D. Schwartz, Blue Raven Partners, L.P., and the Alice N. Schwartz Revocable Trust. The amendment reflects changes in beneficial ownership following the death of Alice N. Schwartz, who passed away on Septe...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz and the Alice N. Schwartz Revocable Trust. The amendment updates the ownership details following the death of Alice N. Schwartz on September 25, 2025. Norman D. Schwartz now holds beneficial ownership of 3,228,92...

This Amendment No. 4 to Schedule 13D, filed by Material Impact Partners II, LLC, Material Impact Fund II, L.P., Adam Sharkawy, and Carmichael Roberts, updates the reporting persons' holdings and percentage ownership in Nauticus Robotics, Inc. following several corporate events. These events include the Series B Preferr...

The filing is an amendment to Schedule 13D for MultiSensor AI Holdings, Inc., detailing significant changes in ownership and transactions involving the company's common stock. The Reporting Persons, including 325 Capital Master Fund LP and other entities, have acquired a substantial number of shares through private pla...

This Amendment No. 4 to Schedule 13D, filed by Material Impact Partners II, LLC and related entities, updates the ownership details of Nauticus Robotics, Inc. following a Series B Preferred Stock financing and a 1 for 9 reverse stock split on September 5, 2025. The amendment reflects changes in the percentage ownership...

This Amendment No. 1 to the Schedule 13D filed by Lu Zhijian with respect to AvePoint, Inc. discloses a secondary offering of Common Stock. On September 16, 2025, the Reporting Person, along with other selling security holders, entered into an underwriting agreement with AvePoint, Inc. and several underwriters. The Rep...

ValueAct Holdings, L.P. has filed an amendment to its Schedule 13D, disclosing a reduction in its stake in Insight Enterprises, Inc. As of October 28, 2025, ValueAct Holdings and its affiliates own 1,666,739 shares of Common Stock, representing approximately 5.3% of the Issuer's outstanding shares. This marks a signifi...

This Amendment No.1 to the Schedule 13D filed by TransCode Therapeutics, Inc. on October 16, 2025, updates the disclosure regarding the Contingent Value Rights Agreement (CVR Agreement) and the Amended and Restated Certificate of Designation. The CVR Agreement, effective October 8, 2025, entitles each holder of Common ...

This filing represents Amendment No. 1 to the Schedule 13D previously filed by Seven Fleet Master Fund LP, Seven Fleet Capital Management LP, Seven Fleet Capital Management GP LLC, and Dr. Brian Liu regarding their holdings in CG Oncology, Inc. The amendment reflects an internal restructuring into a master-feeder struc...

This Amendment No. 17 to the Schedule 13D for Bioceres Crop Solutions Corp. reports a decrease in the shares beneficially owned by the Reporting Persons, Bioceres Group Limited and Bioceres LLC, from 9,432,896 to 3,189,161. This reduction is due to the settlement of certain financial obligations through payment-in-kind...

This Amendment No. 17 to the Schedule 13D filed by Bioceres Group Limited and Bioceres LLC reports a decrease in the shares beneficially owned by the Reporting Persons. The decrease is a result of the settlement of certain financial obligations through payment-in-kind made in shares relating to private transactions. As...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz, Steven D. Schwartz, Blue Raven Partners, L.P., and the Alice N. Schwartz Revocable Trust. The amendment reflects changes in beneficial ownership following the death of Alice N. Schwartz on September 25, 2025. No...

This filing is an amendment to the Schedule 13D for Bio-Rad Laboratories, Inc., filed by Norman D. Schwartz and the Alice N. Schwartz Revocable Trust. The amendment updates the ownership details following the death of Alice N. Schwartz on September 25, 2025. Norman D. Schwartz now holds beneficial ownership of 3,228,92...

This Amendment No. 1 to the Schedule 13D filed by Lu Zhijian for AvePoint, Inc. details a secondary offering of Common Stock. On September 16, 2025, the selling security holders, including Lu Zhijian, entered into an underwriting agreement with Jefferies LLC, Morgan Stanley & Co. LLC, Oversea-Chinese Banking Corporatio...

MultiSensor AI Holdings, Inc. filed an amendment to its Schedule 13D, disclosing changes in ownership and transactions related to its common stock. The amendment includes details about the acquisition of shares and warrants by 325 Capital Master Fund LP and other reporting persons. The transactions are part of a privat...

Yunqi Capital Limited and other Reporting Persons have filed Amendment No. 3 to their Schedule 13D regarding their ownership of STAAR SURGICAL CO's common stock. The amendment includes an open letter to the board of directors of STAAR SURGICAL CO, opposing the adjournment of the special meeting of stockholders and urgi...

Voss Capital, LLC filed Amendment No. 3 to its Schedule 13D regarding its holdings in International Money Express, Inc. (IMXI). The amendment reflects that Voss Capital, through its managed accounts, holds 769,265 shares of IMXI common stock, representing approximately 2.6% of the outstanding shares. The shares were pu...

RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, filed Amendment No. 8 to their Schedule 13D/A for VOR Biopharma Inc. The amendment reports the sale of shares by RA Capital Healthcare Fund, L.P. in multiple transactions between October 21, 2025, and October 27, 2025. The shares were sold at wei...

Fairmount Funds Management LLC and Fairmount Healthcare Fund II GP LLC filed Amendment No. 7 to their Schedule 13D regarding their holdings in Viridian Therapeutics, Inc. The amendment reports that Fairmount Funds Management LLC, through its investment in Fairmount Healthcare Fund II LP, now holds 16,025,330 shares of ...

Trian Fund Management, L.P., along with General Catalyst Group Management, LLC, has submitted a non-binding proposal to acquire all outstanding ordinary shares of Janus Henderson Group plc not currently owned by Trian for $46.00 per share in cash. This proposal represents a significant premium to the closing price of t...

Yunqi Capital Limited and other Reporting Persons have filed Amendment No. 3 to their Schedule 13D regarding their holdings in STAAR Surgical Co. The amendment includes an open letter to the board of directors of STAAR Surgical Co, urging them to allow stockholders to vote on the Proposed Merger and not to commence a n...

This Amendment No. 1 to Schedule 13D, filed by Mir Imran and InCube Labs, L.L.C., updates the ownership details of Class A Common Stock of Rani Therapeutics Holdings, Inc. The amendment includes the purchase of 2,083,334 shares of Class A Common Stock and 2,083,334 warrants by Mir Imran in a private placement on Octobe...